Cangen Biotechnologies and Olympus to Collaborate

Cangen Biotechnologies announced a research collaboration with Olympus Corporation for the development of a hybrid DNA-based and protein-based diagnostic test for use in the detection of lung cancer. This collaboration will provide Cangen Biotechnologies with access to Olympus' microarray technology to enable the DNA-based portion of the test allowing high-throughput testing for lung cancer. Under the terms of the agreement, Olympus is responsible for refining and further developing its microarray technology in an effort to accommodate Cangen's development of the hybrid DNA-based and protein-based diagnostic test for the detection of lung cancer.

()a href="http://home.businesswire.com/portal/site/biospace/index.jsp?epi-content=GENERIC&newsId=20050525005687&ndmHsc=v2*A1116414000000*B1117061838000*DgroupByDate*J2*N1000122&newsLang=en&beanID=1229976837&viewID=news_view" target="_blank">BioSpace